Microsite Matches Oncology Sponsors with Canadian Investigators
Scimega Research, an oncology-focused CRO, has launched its new Reverse Feasibility Resource Center
Scimega Research, (www.scimega.com) an oncology-focused CRO, has launched its new Reverse Feasibility Resource Center, that is aimed at matching U.S. oncology sponsors in need of Canadian investigators and their patients.
This microsite will be updated regularly to highlight Canada’s expertise in both early and late phase oncology trials. It currently features important information such as the number of oncology sites, key investigators, and the size of the catchment areas for each of the ten Canadian provinces. Sponsors can sign up to receive free quarterly updates on the types of trials Scimega’s Reverse Feasibility Champions are looking to participate in. This Oncology Trial Needs Report for Canada will highlight the number of sites actively looking for a trial, including lines of treatment, tumor types and targets.
Read the full release here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Full Phase IIIb BATURA Trial Results Show Airsupra Cuts Severe Exacerbations by 47% in Mild Asthma
May 20th 2025Results from the pivotal BATURA trial show that Airsupra (albuterol/budesonide) significantly outperformed albuterol monotherapy in reducing severe asthma exacerbations and systemic corticosteroid exposure, reinforcing its role as a next-generation, anti-inflammatory rescue therapy for mild asthma patients.
